바이오테크 보도자료
-
- Humanigen Expands its anti-GM-CSF Patent Portfolio
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the company has ...
- 2021년 03월 18일
-
- New syringe barrel size reduces the number of assembly fluid changeovers required for automated manufacturing processes
- Nordson EFD, a Nordson company (NASDAQ: NDSN) and a leading precision fluid dispensing systems manufacturer, introduces the largest sized syringe barrel in its Optimum dispensing components line. The 70cc syringe barrel holds more assembly fluids,...
- 2021년 03월 17일
-
- Grand Prize Winners Selected in $6M XPRIZE Rapid Covid Testing Competition to Create Fast, Frequent, Cheap, and Easy-to-Use Solutions
- XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, is pleased to announce today the five winning teams in the $6M XPRIZE Rapid Covid Testing competition, with each winner creating hig...
- 2021년 03월 17일
-
- PCI Pharma Broadens Clinical Trial Service Offerings at Berlin Facility, Bringing Worldwide Access to Clients in the European Union
- PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a new milestone in its global Clinical footprint with the expansion of cold chain clinical supply storage and distribu...
- 2021년 03월 17일
-
- Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Take...
- 2021년 03월 16일
-
- ReNew Power Announces Its Addition to the World Economic Forum’s Global Lighthouse Network of Companies Leading in the Area of Technology-Enabled, Sustainable Growth
- ReNew Power (“ReNew” or “the Company”), India’s leading renewable energy company, today announced that it has been named to the World Economic Forum’s (WEF) Global Lighthouse Network, which recognizes companies using new technologies to achieve en...
- 2021년 03월 16일
-
- Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) announced the results from a subgroup analy...
- 2021년 03월 16일
-
- Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector
- Waters Corporation (NYSE:WAT) today released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight (TOF) mass spectrometer (MS) for small molecule analysis for pharmaceutical, academic, food, and forensics applications....
- 2021년 03월 16일
-
- Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade[1]
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approxi...
- 2021년 03월 12일
-
- Humanigen Announces $80 Million Loan Facility from Hercules Capital
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, has obtained a term loan facili...
- 2021년 03월 12일
-
- Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for lanadelumab subcutaneous injection, a monoclo...
- 2021년 03월 12일
-
- Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial result...
- 2021년 03월 12일
전시회
